Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score